Obesity, part 2 : the potential risk factor contributing to clinical manifestations of COVID 19

ZOOM PLATFORM. ENGLISH LANGUAGE

This webinar is under CPD accreditation in MOHAP

We invite physicians, clinical pharmacists and pharmacists to the Obesity, part 2 : the potential risk factor contributing to clinical manifestations of COVID 19 webinar.

Obesity is a potential risk factor contributing to clinical manifestations of COVID-19 it has reached epidemic proportions in the much of the developed world, resulting in significant morbidity. Several of these obesity-related morbidities have been linked to a higher risk of death from coronavirus infection in 2019 (COVID-19).

Besides advanced age and the presence of numerous comorbidities as most important contributors to an elevated risk of severe disease and deadly outcome from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19), there is now emerging evidence that overweight and obesity predispose to severe symptoms and negative prognosis. Surprisingly, the severity of COVID-19 appears to rise with increasing body mass index (BMI). The association between COVID-19 outcomes and overweight/obesity has biological and physiological plausibility.

During this webinar with Dr Talar Ahmad we will explain: the genomic structure of SARS-CoV-2, mechanisms of virus entry, the life- cycle- of a coronavirus, the role of ACE2 in COVID-19 pathophysiology, including factors influencing ACE2 expression and activity in relation to COVID-19 severity.

In addition, we will discuss the relevant pathological changes resulting from SARS-CoV-2 infection. Obesity and other comorbidities will be also explained.

 Obesity as the risk factor for severe COVID-19 in accompanied with other comorbidities.